Will the FDA approve AstraZeneca's new cancer drug for any indication by December 31, 2027?

An FDA advisory panel voted against AstraZeneca's new cancer drug. While not binding, panel rejections often precede a full FDA rejection, but the company may pursue other indications or provide more data.

Implied probability (Yes)

25%

Closes

2029-07-30